0.6376

1.64% -0.00295

Outlook Therapeutics Inc (OTLK)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.6405

Offen:

$0.6397

24-Stunden-Volumen:

1.78M

Relative Volume:

0.11

Marktkapitalisierung:

$154.68M

Einnahmen:

$424.90K

Nettoeinkommen (Verlust:

$-94.02M

KGV:

-0.2566

EPS:

-2.4842

Netto-Cashflow:

$-51.25M

1W Leistung:

+0.59%

1M Leistung:

-38.24%

6M Leistung:

+40.75%

1J Leistung:

-31.99%

1-Tages-Spanne:

$0.621

$0.6405

1-Wochen-Bereich:

$0.6174

$0.6962

52-Wochen-Spanne:

$0.1611

$2.5375

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Firmenname

Outlook Therapeutics Inc

Sektor

Healthcare (1086)

Branche

Biotechnology (606)

Telefon

(609) 619-3990

Adresse

111 S. WOOD AVENUE, ISELIN, NJ

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-14

Neueste SEC-Einreichungen

OTLK's Discussions on Twitter

Compare OTLK vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OTLK Outlook Therapeutics Inc	0.6374	155.43M	424.90K	-94.02M	-51.25M	-2.4842
VRTX Vertex Pharmaceuticals Inc	521.27	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.21	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,006.01	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.71	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.29	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-08-28	Herabstufung	Guggenheim	Buy → Neutral
2024-12-02	Herabstufung	Chardan Capital Markets	Buy → Neutral
2024-03-27	Hochstufung	BTIG Research	Neutral → Buy
2024-02-15	Hochstufung	Chardan Capital Markets	Neutral → Buy
2024-01-25	Hochstufung	Guggenheim	Neutral → Buy
2023-12-27	Hochstufung	CapitalOne	Equal Weight → Overweight
2023-08-31	Herabstufung	Chardan Capital Markets	Buy → Neutral
2023-08-31	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-30	Herabstufung	BTIG Research	Buy → Neutral
2023-08-30	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-08-30	Herabstufung	CapitalOne	Overweight → Equal Weight
2023-08-30	Herabstufung	Guggenheim	Buy → Neutral
2023-07-13	Eingeleitet	CapitalOne	Overweight
2023-04-03	Eingeleitet	Guggenheim	Buy
2023-02-06	Eingeleitet	Cantor Fitzgerald	Overweight
2022-10-31	Eingeleitet	BTIG Research	Buy
2022-09-13	Eingeleitet	Chardan Capital Markets	Buy
2019-09-11	Eingeleitet	Ladenburg Thalmann	Buy
2019-05-16	Eingeleitet	Oppenheimer	Outperform
2019-04-22	Eingeleitet	Ascendiant Capital Markets	Buy

Alle ansehen

Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten

Sep 08, 2026

These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits

Sep 08, 2026

Sep 07, 2026

AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 07, 2026

OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits

Sep 07, 2026

Sep 06, 2026

Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits

Sep 06, 2026

OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits

Sep 06, 2026

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits

Sep 06, 2026

Sep 05, 2026

Outlook Therapeutics Stock Price Forecast. Should You Buy OTLK? - StockInvest.us

Sep 05, 2026

Sep 03, 2026

People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - BioBuzz

Sep 03, 2026

Sep 02, 2026

CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan

Sep 02, 2026

Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - Stock Titan

Sep 02, 2026

Aug 28, 2026

Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail

Aug 28, 2026

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm

Aug 28, 2026

Lundquist appointed chief financial officer at Outlook Therapeutics of Iselin - ROI-NJ

Aug 28, 2026

Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - VisionMonday.com

Aug 28, 2026

Aug 27, 2026

Outlook Therapeutics appoints Kevin Lundquist as CFO as Lawrence Kenyon to depart - TradingView

Aug 27, 2026

Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026 - marketscreener.com

Aug 27, 2026

Aug 19, 2026

Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo

Aug 19, 2026

Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan

Aug 19, 2026